Primary lateral sclerosis and early upper motor neuron disease: Characteristics of a cross-sectional population

Christina N. Fournier, Alyssa Murphy, Lorena Loci, Hiroshi Mitsumoto, Catherine Lomen-Hoerth, Yasushi Kisanuki, Zachary Simmons, Nicholas J. Maragakis, April L. McVey, Tawfiq Al-Lahham, Terry D. Heiman-Patterson, Jinsy Andrews, Erin McDonnell, Merit Cudkowicz, Nazem Atassi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: The goals of this study were to characterize clinical and electrophysiologic findings of subjects with upper motor neuron disease and to explore feasibility of clinical trials in this population. Methods: Twenty northeast amyotrophic lateral sclerosis consortium (northeast amyotrophic lateral sclerosis) sites performed chart reviews to identify active clinical pure upper motor neuron disease patients. Patients with hereditary spastic paraplegia or meeting revised El Escorial electrodiagnostic criteria for amyotrophic lateral sclerosis were excluded. Patients were classified into 2 groups according to the presence or absence of minor electromyography (EMG) abnormalities. Results: Two hundred thirty-three subjects with upper motor neuron disease were identified; 217 had available EMG data. Normal EMGs were seen in 140 subjects, and 77 had minor denervation. Mean disease duration was 84 (680) months for the entire cohort with no difference seen between the 2 groups. No difference was seen in clinical symptoms, disability, or outcome measures between the 2 groups after correcting for multiple comparisons. Conclusions: Minor EMG abnormalities were not associated with phenotypic differences in a clinical upper motor neuron disease population. These findings suggest that subtle EMG abnormalities can not necessarily be used as a prognostic tool in patients with clinical upper motor neuron disease. This study also demonstrates the availability of a large number of patients with upper motor neuron diseases within the northeast amyotrophic lateral sclerosis network and suggests feasibility for conducting clinical trials in this population.

Original languageEnglish (US)
Pages (from-to)99-105
Number of pages7
JournalJournal of Clinical Neuromuscular Disease
Volume17
Issue number3
DOIs
StatePublished - Jan 1 2016

Fingerprint

Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Electromyography
Population
Hereditary Spastic Paraplegia
Clinical Trials
Denervation
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Fournier, Christina N. ; Murphy, Alyssa ; Loci, Lorena ; Mitsumoto, Hiroshi ; Lomen-Hoerth, Catherine ; Kisanuki, Yasushi ; Simmons, Zachary ; Maragakis, Nicholas J. ; McVey, April L. ; Al-Lahham, Tawfiq ; Heiman-Patterson, Terry D. ; Andrews, Jinsy ; McDonnell, Erin ; Cudkowicz, Merit ; Atassi, Nazem. / Primary lateral sclerosis and early upper motor neuron disease : Characteristics of a cross-sectional population. In: Journal of Clinical Neuromuscular Disease. 2016 ; Vol. 17, No. 3. pp. 99-105.
@article{17d629536d4f415bb45050f3d4dac8fa,
title = "Primary lateral sclerosis and early upper motor neuron disease: Characteristics of a cross-sectional population",
abstract = "Objectives: The goals of this study were to characterize clinical and electrophysiologic findings of subjects with upper motor neuron disease and to explore feasibility of clinical trials in this population. Methods: Twenty northeast amyotrophic lateral sclerosis consortium (northeast amyotrophic lateral sclerosis) sites performed chart reviews to identify active clinical pure upper motor neuron disease patients. Patients with hereditary spastic paraplegia or meeting revised El Escorial electrodiagnostic criteria for amyotrophic lateral sclerosis were excluded. Patients were classified into 2 groups according to the presence or absence of minor electromyography (EMG) abnormalities. Results: Two hundred thirty-three subjects with upper motor neuron disease were identified; 217 had available EMG data. Normal EMGs were seen in 140 subjects, and 77 had minor denervation. Mean disease duration was 84 (680) months for the entire cohort with no difference seen between the 2 groups. No difference was seen in clinical symptoms, disability, or outcome measures between the 2 groups after correcting for multiple comparisons. Conclusions: Minor EMG abnormalities were not associated with phenotypic differences in a clinical upper motor neuron disease population. These findings suggest that subtle EMG abnormalities can not necessarily be used as a prognostic tool in patients with clinical upper motor neuron disease. This study also demonstrates the availability of a large number of patients with upper motor neuron diseases within the northeast amyotrophic lateral sclerosis network and suggests feasibility for conducting clinical trials in this population.",
author = "Fournier, {Christina N.} and Alyssa Murphy and Lorena Loci and Hiroshi Mitsumoto and Catherine Lomen-Hoerth and Yasushi Kisanuki and Zachary Simmons and Maragakis, {Nicholas J.} and McVey, {April L.} and Tawfiq Al-Lahham and Heiman-Patterson, {Terry D.} and Jinsy Andrews and Erin McDonnell and Merit Cudkowicz and Nazem Atassi",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/CND.0000000000000102",
language = "English (US)",
volume = "17",
pages = "99--105",
journal = "Journal of Clinical Neuromuscular Disease",
issn = "1522-0443",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Fournier, CN, Murphy, A, Loci, L, Mitsumoto, H, Lomen-Hoerth, C, Kisanuki, Y, Simmons, Z, Maragakis, NJ, McVey, AL, Al-Lahham, T, Heiman-Patterson, TD, Andrews, J, McDonnell, E, Cudkowicz, M & Atassi, N 2016, 'Primary lateral sclerosis and early upper motor neuron disease: Characteristics of a cross-sectional population', Journal of Clinical Neuromuscular Disease, vol. 17, no. 3, pp. 99-105. https://doi.org/10.1097/CND.0000000000000102

Primary lateral sclerosis and early upper motor neuron disease : Characteristics of a cross-sectional population. / Fournier, Christina N.; Murphy, Alyssa; Loci, Lorena; Mitsumoto, Hiroshi; Lomen-Hoerth, Catherine; Kisanuki, Yasushi; Simmons, Zachary; Maragakis, Nicholas J.; McVey, April L.; Al-Lahham, Tawfiq; Heiman-Patterson, Terry D.; Andrews, Jinsy; McDonnell, Erin; Cudkowicz, Merit; Atassi, Nazem.

In: Journal of Clinical Neuromuscular Disease, Vol. 17, No. 3, 01.01.2016, p. 99-105.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Primary lateral sclerosis and early upper motor neuron disease

T2 - Characteristics of a cross-sectional population

AU - Fournier, Christina N.

AU - Murphy, Alyssa

AU - Loci, Lorena

AU - Mitsumoto, Hiroshi

AU - Lomen-Hoerth, Catherine

AU - Kisanuki, Yasushi

AU - Simmons, Zachary

AU - Maragakis, Nicholas J.

AU - McVey, April L.

AU - Al-Lahham, Tawfiq

AU - Heiman-Patterson, Terry D.

AU - Andrews, Jinsy

AU - McDonnell, Erin

AU - Cudkowicz, Merit

AU - Atassi, Nazem

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objectives: The goals of this study were to characterize clinical and electrophysiologic findings of subjects with upper motor neuron disease and to explore feasibility of clinical trials in this population. Methods: Twenty northeast amyotrophic lateral sclerosis consortium (northeast amyotrophic lateral sclerosis) sites performed chart reviews to identify active clinical pure upper motor neuron disease patients. Patients with hereditary spastic paraplegia or meeting revised El Escorial electrodiagnostic criteria for amyotrophic lateral sclerosis were excluded. Patients were classified into 2 groups according to the presence or absence of minor electromyography (EMG) abnormalities. Results: Two hundred thirty-three subjects with upper motor neuron disease were identified; 217 had available EMG data. Normal EMGs were seen in 140 subjects, and 77 had minor denervation. Mean disease duration was 84 (680) months for the entire cohort with no difference seen between the 2 groups. No difference was seen in clinical symptoms, disability, or outcome measures between the 2 groups after correcting for multiple comparisons. Conclusions: Minor EMG abnormalities were not associated with phenotypic differences in a clinical upper motor neuron disease population. These findings suggest that subtle EMG abnormalities can not necessarily be used as a prognostic tool in patients with clinical upper motor neuron disease. This study also demonstrates the availability of a large number of patients with upper motor neuron diseases within the northeast amyotrophic lateral sclerosis network and suggests feasibility for conducting clinical trials in this population.

AB - Objectives: The goals of this study were to characterize clinical and electrophysiologic findings of subjects with upper motor neuron disease and to explore feasibility of clinical trials in this population. Methods: Twenty northeast amyotrophic lateral sclerosis consortium (northeast amyotrophic lateral sclerosis) sites performed chart reviews to identify active clinical pure upper motor neuron disease patients. Patients with hereditary spastic paraplegia or meeting revised El Escorial electrodiagnostic criteria for amyotrophic lateral sclerosis were excluded. Patients were classified into 2 groups according to the presence or absence of minor electromyography (EMG) abnormalities. Results: Two hundred thirty-three subjects with upper motor neuron disease were identified; 217 had available EMG data. Normal EMGs were seen in 140 subjects, and 77 had minor denervation. Mean disease duration was 84 (680) months for the entire cohort with no difference seen between the 2 groups. No difference was seen in clinical symptoms, disability, or outcome measures between the 2 groups after correcting for multiple comparisons. Conclusions: Minor EMG abnormalities were not associated with phenotypic differences in a clinical upper motor neuron disease population. These findings suggest that subtle EMG abnormalities can not necessarily be used as a prognostic tool in patients with clinical upper motor neuron disease. This study also demonstrates the availability of a large number of patients with upper motor neuron diseases within the northeast amyotrophic lateral sclerosis network and suggests feasibility for conducting clinical trials in this population.

UR - http://www.scopus.com/inward/record.url?scp=84959901450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959901450&partnerID=8YFLogxK

U2 - 10.1097/CND.0000000000000102

DO - 10.1097/CND.0000000000000102

M3 - Article

C2 - 26905909

AN - SCOPUS:84959901450

VL - 17

SP - 99

EP - 105

JO - Journal of Clinical Neuromuscular Disease

JF - Journal of Clinical Neuromuscular Disease

SN - 1522-0443

IS - 3

ER -